Ad hoc announcement pursuant to Art. 53 LR Ligelizumab, a high-affinity anti-IgE antibody, demonstrated superiority compared with placebo at Week 12 in Phase III PEARL 1 and PEARL 2 trials, but not
Paediatric Allergic Rhinitis: Common but undiagnosed in Ireland and UK imt.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from imt.ie Daily Mail and Mail on Sunday newspapers.
Eczema: What Causes Eczema? Warning Signs To Look Out For thehealthsite.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehealthsite.com Daily Mail and Mail on Sunday newspapers.
Dit artikel delen
Share this article
LEIDEN, The Netherlands, June 4, 2021 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that an agreement has been reached with the Spanish Ministry of Health to grant reimbursement for RUCONEST® (conestat alfa) in Spain.
RUCONEST® is the first and only plasma-free recombinant human C1 esterase inhibitor (rhC1INH) protein replacement therapy approved for the treatment of acute hereditary angioedema (HAE) attacks in adults and children aged 2 years and over.
1
HAE is a rare genetic condition characterized by recurrent, unpredictable episodic swellings of mucosal or cutaneous sites, causing pain, disfigurement, and disability, which last for hours and, occasionally, several days.
LEIDEN, The Netherlands, June 4, 2021 /PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that an agreement has been reached